Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.
10.3346/jkms.2016.31.12.1937
- Author:
Soyoung LEE
1
;
Han Wool KIM
;
Kyung Hyo KIM
Author Information
1. Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea. kaykim@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Antibody;
Hepatitis A Virus;
Hepatitis B Virus;
Intravenous Immunoglobulin
- MeSH:
Antibodies*;
Antibody Formation;
Hepatitis A Antibodies;
Hepatitis A virus;
Hepatitis A*;
Hepatitis B virus*;
Hepatitis B*;
Hepatitis*;
Humans;
Immunity, Humoral;
Immunoglobulin G;
Immunoglobulins*;
Immunoglobulins, Intravenous;
Incidence;
Japan;
Korea;
Plasma;
Seroepidemiologic Studies;
Vaccination
- From:Journal of Korean Medical Science
2016;31(12):1937-1942
- CountryRepublic of Korea
- Language:English
-
Abstract:
The worldwide seroprevalence of hepatitis A virus (HAV) and hepatitis B virus (HBV) has changed over the last two decades, indicating a declining incidence of HAV and HBV infections. Therefore, vaccinations against HAV and HBV are recommended for unimmunized people before traveling to an endemic area. Unfortunately, primary antibody deficiency (PAD) patients can only obtain humoral immunity through intravenous immunoglobulin G (IVIG) replacement and not from vaccination because of a defect in antibody production. However, few studies have analyzed the titers of antibodies against HAV or HBV in IVIG products. In this study, the titers of anti-HAV and anti-HBs antibodies were measured in nineteen lots of IVIG products from five manufacturers from three countries (A, B from Korea; C, D from Japan; and E from the USA), and trough titers in plasma were estimated. Concentrations of anti-HAV antibody ranged from 1,888–8,927 mIU/mL and estimated trough titers exceeded the minimal protective value in all evaluated IVIG products. Concentrations of anti-HBs antibody ranged from 438–965 mIU/mL in products A and B and were 157, 123, and 1,945 mIU/mL in products C, D, and E, respectively. Estimated trough titers in products A, B, and E exceeded the minimal protective value but those in products C and D did not reach this threshold. These data demonstrated that available IVIG products generally provide sufficient antibodies against HAV and HBV to protect patients with PAD, although the trough concentrations of anti-HBs antibody in two IVIG products did not reach the minimum protective value.
